{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:01:07Z","timestamp":1785459667578,"version":"3.56.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100005366","name":"Universitetet i Oslo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hemolytic interference may impact various laboratory tests, including coagulation analyses. Apixaban is the most commonly used direct oral anticoagulant in Norway, and there is lacking knowledge on how apixaban concentration measurements might be influenced by hemolysis. Moreover, hemolysis\u2010induced alterations in apixaban levels could potentially impact the risk of bleeding in specific clinical scenarios. We wanted to study whether hemolysis would increase apixaban concentration and investigate the impact of hemolytic interference on apixaban concentration measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood samples from 20 apixaban\u2010treated patients and 8 healthy controls were hemolyzed in vitro by a freeze method. The degree of hemolysis was measured with plasma free hemoglobin (PfHb) at baseline and two levels of hemolysis. Apixaban concentration was measured in plasma using both the chromogenic anti\u2010Xa method and the ultraperformance liquid chromatography mass spectrometry (UPLC\u2010MS). Thrombin generation assay was performed to assess coagulability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      UPLC\u2010MS measurements showed a mean concentration change of \u22121.66% (\u00b13.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005) and anti\u2010Xa assay showed a mean concentration change of 3.37% (\u00b16.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.09) with increasing hemolysis. Thrombin generation lagtime decreased, and endogenous thrombin potential and peak thrombin increased with increasing hemolysis in both the control group and the apixaban group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Apixaban concentration measurements by anti\u2010Xa assay and UPLC\u2010MS were not affected by hemolysis to a clinically relevant extent. Furthermore, hemolysis did not lead to hypocoagulability when assessed by thrombin generation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijlh.14311","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T04:49:52Z","timestamp":1716958192000},"page":"946-952","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Does in vitro hemolysis affect measurements of plasma apixaban concentration by\n                    <scp>UPLC\u2010MS<\/scp>\n                    and anti\u2010Xa assay?"],"prefix":"10.1111","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7412-4554","authenticated-orcid":false,"given":"Henriette","family":"R\u00f8ed\u2010Undlien","sequence":"first","affiliation":[{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina Haagenrud","family":"Schultz","sequence":"additional","affiliation":[{"name":"Research Institute for Internal Medicine Oslo University Hospital  Oslo Norway"},{"name":"Department of Haematology Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6323-9559","authenticated-orcid":false,"given":"Erik Koldberg","family":"Amundsen","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry Oslo University Hospital  Oslo Norway"},{"name":"Department of Life Sciences and Health Oslo Metropolitan University  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit M.","family":"Wollmann","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital  Oslo Norway"},{"name":"Department of Pharmacy, Section for Pharmacology and Pharmaceutical Biosciences University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali R.","family":"Akerkar","sequence":"additional","affiliation":[{"name":"Department of Health Registries Norwegian Institute of Public Health  Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Lagethon","family":"Bj\u00f8rnstad","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"},{"name":"Department of Cardiothoracic Surgery Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/10408363.2011.600228"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.11.010"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.013672"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100032\u20101328972"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm\u20102019\u20100135"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.5858\/2006\u2010130\u2010181\u2010iobclo"},{"key":"e_1_2_12_8_1","volume-title":"Drug Consumption in Norway 2015\u20132019\u2014Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database","author":"Sommerschild H","year":"2020"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12106"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1160\/th13\u201004\u20100274"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.0364"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2019.27.1.33"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13188"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2013\u20100572\u2010OA"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.12.229"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2011.07.015"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm\u20102018\u20100193"},{"key":"e_1_2_12_18_1","first-page":"157","volume-title":"Advances in Clinical Chemistry","author":"Lippi G","year":"2015"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.2009.218"},{"key":"e_1_2_12_20_1","volume-title":"Apixaban\/INNOVANCE Anti\u2010Xa. Application Description","author":"GmbH SHDP","year":"2022"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13743"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.22.0439"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1627480"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12702"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12113"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017004820"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.12.020"},{"key":"e_1_2_12_28_1","volume-title":"Interference Testing in Clinical Chemistry; Approved Guideline","author":"Clinical and Laboratory Standards Institute","year":"2005"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm\u20102021\u20101227"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e3280116c62"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.10.023"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.11.190"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.14311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijlh.14311","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.14311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:04:05Z","timestamp":1773911045000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.14311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/ijlh.14311"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.14311","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"2024-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}